Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Comparison of incidence rate of posterior capsule opacification in eyes implanted with three-piece acrylic intraocular lenses

Poster Details

First Author: K.Ishii JAPAN

Co Author(s):    N. Kurita   Y. Kato                 

Abstract Details

Purpose:

We previously reported the posterior capsulotomy rate for the treatment of posterior capsule opacification (PCO) with the acrylic intraocular lenses (IOLs) implantation in the XXXⅡ. For further evaluation, we made a comparative review of the length of time until posterior capsulotomy and the survival rate in a unified observation period in eyes implanted with three-piece IOLs.

Setting:

Saitama Red Cross Hospital

Methods:

This retrospective study enrolled 8,971 eyes (male 4,607 eyes, female 4,364 eyes, mean age 72.2±10.8 years old) of patients who received cataract surgery implanted with 6.0 mm diameter three-piece acrylic IOLs from January 2002 through December 2007 at our Departments of Ophthalmology. In this study, Kaplan-Meier survival estimate was used equating Neodymium: YAG (Nd: YAG) with death, and was used to evaluate the survival rate.

Results:

The length of time until posterior capsulotomy and the survival rate during the 70-month observation period were MA60BM (Alcon) 41.3 months and 97.1%, YA60BB (HOYA) 30.4 months and 88.7%, YA60BBR (HOYA) 30.0 months and 88.8%, AN-6K (Kowa) 35.6 months and 91.9%. The survival rates of MA60AT and AN-6K were significantly higher than the other IOLs (p<0.001).

Conclusions:

The result showed that the incidence of posterior capsulotomy was lower in eyes implanted with IOLs with sharp optic edge profile.

Financial Disclosure:

NONE

Back to Poster listing